Taichung Veterans General Hospital, No. 1650 Taiwan Boulevard, Sec. 4
Welcome,         Profile    Billing    Logout  
 5 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Yang, Sheng-Shun
FOENIX-CCA4, NCT05727176: Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

Recruiting
2
120
Europe, Japan, US, RoW
TAS-120, Futibatinib
Taiho Oncology, Inc.
Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
06/25
06/26
NCT05276297 / 2021-003567-10: A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy

Active, not recruiting
2
184
Europe, RoW
GSK3228836, Bepirovirsen, GSK3528869A, Control
GlaxoSmithKline, GlaxoSmithKline Biologicals
Hepatitis B, Chronic
02/26
02/26
NCT03866187 / 2017-001452-55: Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection

Terminated
1/2
135
Europe, RoW
ChAd155-hIi-HBV low dose formulation, ChAd155-hIi-HBV high dose formulation, HBc-HBs/AS01B-4 low dose formulation, HBc-HBs/AS01B-4 high dose formulation, MVA-HBV low dose formulation, MVA-HBV high dose formulation, Placebo
GlaxoSmithKline, GlaxoSmithKline Biologicals
Hepatitis B, Chronic
10/24
10/24
AMBER, NCT02817633: A Study of TSR-022 in Participants With Advanced Solid Tumors

Hourglass Oct 2019 - Mar 2020 : From AMBER trial
Checkmark From AMBER trial at SITC 2018 [screenshot]
Nov 2018 - Nov 2018: From AMBER trial at SITC 2018 [screenshot]
Checkmark From AMBER trial in combination with TSR-022 at SITC 2018
Nov 2018 - Nov 2018: From AMBER trial in combination with TSR-022 at SITC 2018
Recruiting
1
447
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
Tesaro, Inc.
Neoplasms
04/25
04/27
NCT05092074: Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection

Recruiting
N/A
100
RoW
Vosevi 400/100/100 Oral Tablet
National Taiwan University Hospital
Hepatitis C Virus Infection, Treatment Side Effects, Adherence, Treatment, Effect of Drug
12/22
02/23
NCT04732832: HCV Reinfection in HD Patients Achieving SVR

Recruiting
N/A
350
RoW
National Taiwan University Hospital
Hepatitis C Virus Infection, Hepatitis C Virus Infection, Response to Therapy of, Hemodialysis Complication
02/24
03/24
NCT04768517: HCV Reinfection in in HIV/HCV-coinfected Patients Achieving SVR by Antiviral Therapy

Recruiting
N/A
300
RoW
National Taiwan University Hospital
Hepatitis C Virus Infection, Hepatitis C Virus Infection, Response to Therapy of, Human Immunodeficiency Virus (HIV) Coinfection
02/24
03/24
NCT06277037: Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)

Recruiting
N/A
50
Europe, US, RoW
Non-interventional
Arbutus Biopharma Corporation
Long Term Follow-up
08/29
10/29
NCT04180072: Atezolizumab Plus Bevacizumab With HCC and HBV Infection

Active, not recruiting
N/A
51
RoW
Atezolizumab, Tecentriq, Bevacizumab, Avastin
National Health Research Institutes, Taiwan, National Taiwan University Hospital, Taipei Veterans General Hospital, Taiwan, Mackay Memorial Hospital, Changhua Christian Hospital, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital, Taichung Veterans General Hospital
Carcinoma, Hepatocellular
12/25
12/25

Download Options